Jonathan Spiker
Overview
Explore the profile of Jonathan Spiker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
14
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Botsis T, Spiker J, Kreimeyer K, Fatteh M, Wehr J, Najjar M, et al.
Stud Health Technol Inform
. 2024 Aug;
316:1854-1855.
PMID: 39176852
There is a critical need for a streamlined process to identify genotype-matched individuals eligible for enrollment into clinical trials and/or targeted therapies, as current methodologies face challenges in integrating diverse...
2.
Botsis T, Murray J, Ghanem P, Balan A, Kernagis A, Hardart K, et al.
JCO Clin Cancer Inform
. 2023 Apr;
7:e2200108.
PMID: 37040583
Purpose: Precision oncology mandates developing standardized common data models (CDMs) to facilitate analyses and enable clinical decision making. Expert-opinion-based precision oncology initiatives are epitomized in Molecular Tumor Boards (MTBs), which...
3.
Kreimeyer K, Spiker J, Botsis T
Stud Health Technol Inform
. 2022 Jul;
295:398-401.
PMID: 35773895
Many decision support methods and systems in pharmacovigilance are built without explicitly addressing specific challenges that jeopardize their eventual success. We describe two sets of challenges and appropriate strategies to...
4.
Kreimeyer K, Dang O, Spiker J, Munoz M, Rosner G, Ball R, et al.
Comput Biol Med
. 2021 Jun;
135:104517.
PMID: 34130003
Background: Our objective was to support the automated classification of Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) reports for their usefulness in assessing the possibility of a...
5.
Spiker J, Kreimeyer K, Dang O, Boxwell D, Chan V, Cheng C, et al.
Drug Saf
. 2020 May;
43(9):905-915.
PMID: 32445187
Introduction: The US FDA receives more than 2 million postmarket reports each year. Safety Evaluators (SEs) review these reports, as well as external information, to identify potential safety signals. With...